Tempus HRD test:

Question 1

Tempus HRD is an “add-on” option.

Answer 1

True

Question 2

For breat specifically, does it need to be added on xT with a normal match? Yes or no.

Answer 2

Yes

Question 3

Any other cancer type, it can be xT solid tumor only, T or F?

Answer 3

True

Question 4

Assesing a tumor for HRD, how do we do this?

Answer 4

1) Analyzing the tumor for presence of variants in HRR genes (BRCA1/2)
2) Genomic instability score
3) Genome-wide loss of heterozygosity
4) RNA expression
5) RAD51 funcational assays

Question 5

What methods does Tempus currently utilize?

Answer 5

1) Presence of variants in HRR genes
2) Genome-wide loss of heterozygosity
3) RNA expression

Question 6

Why does the presence of variants in the HRR gene matter?

Answer 6

Beccause they are the basis for the FDA approved list.

Question 7

What about genome-wide?

Answer 7

reverts back to the two-hit hypothesis

Question 8

RNA expression?

Answer 8

Using RNA allows us to identify a RNA transcript that’s independent of the genomic DNA status.

Question 9

Breast and Ovarian:

Answer 9

Tempus will use the GWLOH test for reporting HRD status in those cancer types.
HRD-DNA test for these two**

Question 10

Prostate and Pancreatic:

Answer 10

RNA expression may be a good method

HRD-RNA test for these two**

Question 11

Is assessment for the presence of HRR variants always part of the xT?

Answer 11

Yes. Regardless of the cancer type.

Question 12

Tempus HRD/DNA report:

Answer 12

• The status is either “positive” or “ not detected”
• percentage of GWLOH w/ reference to tumor subtype is provided
• somatic or germline variants at the bottom are reported. Detected in 23 HRR pathway genes.

Question 13

HRD-DNA

Answer 13

• Breast, Ovarian cancers
• Available as Add-on, xT solid tumor+Normal
• Required sample: 40%

Question 14

HRD-RNA

Answer 14

• All other cancers
• xT solid tumor+ norml match
• xT solid tumor only
• Required sample: 30%

Question 15

Biomarkers utlized for HRD-DNA:

Answer 15

• DNA GWLOH or evidence of biallelic BRCA1/2 loss

Question 16

Biomarkers utlizied for HRD-RNA:

Answer 16

• 20,000 genes (mRNA expression)

Question 17

Source of data for HRD-DNA:

Answer 17

GWLOH: Copy number losses in DNA

- BRCA 1/2 loss: xT sequencing

Question 18

Source of data for HRD-RNA:

Answer 18

RNA sequencing

Question 19

T or F, there is only ONE Tempus HRD test for clinicians to order:

Answer 19

True, the difference is what we do internally once we recieve the order and determine the cancer type.

Question 20

Which of the following methods is NOT utilized by Tempus to assess tumors for HRD?

Answer 20

Genomic instability score

Question 21

Which of the following statements about Tempus HRD are false?

Answer 21

• is a standalone test order option

- additional specimen must be submitted to perform HRD

Question 22

this HRD status is determined by expression score generated from full transcriptome :

Answer 22

HRD-RNA

Question 23

this HRD status is determined by genome-wide LOH of evidence of biallelic BRCA 1/2 loss

Answer 23

HRD- DNA

Question 24

Match the cancer type with the threashold is must reach for a “positive” HRD status to be reported:

Answer 24

Breast- 21% LOH
Ovarian - 17% LOH
Prostate - RNA expression score of 50 or greater